Miami, FLNCT07218926Now EnrollingIRB Ready

Gastrointestinal Neoplasms Clinical Trial in Miami, FL

Access cutting-edge gastrointestinal neoplasms treatment through this clinical trial at a research site in Miami. Study-provided care at no cost to qualified participants.

Sponsored by GlaxoSmithKline

Quick Self-Assessment

See if you qualify for this Miami location

Preparing your pre-screening questions…

Expert Care in Miami

Access gastrointestinal neoplasms specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related gastrointestinal neoplasms treatment provided free

Apply for This Miami Location

Check if you qualify for this gastrointestinal neoplasms clinical trial in Miami, FL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Miami

    Convenient for FL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Miami site if eligible
  4. 4Begin participation

About This Gastrointestinal Neoplasms Study in Miami

The purpose of this study is to find out if a new drug, called IDRX-42 (also known as GSK6042981), is effective in treating adults with a type of cancer called Gastrointestinal Stromal Tumors (GIST) when compared to another drug named sunitinib. The study will see if IDRX-42 works well and is safe for participants whose GIST has spread or cannot be surgically removed, and who have already taken the drug imatinib. Participants whose disease worsens after receiving sunitinib in this study may cross over to receive GSK6042981, at investigator's discretion and if additional eligibility criteria are met.

Sponsor: GlaxoSmithKline

Who Can Participate

Inclusion Criteria

Participants with histologically or cytologically confirmed GIST that is metastatic and/or surgically unresectable.
Documented disease progression on or intolerance to imatinib administered for first-line treatment of unresectable/metastatic disease.
Documented mutation status of KIT and/or PDGFRA using a tissue based next-generation sequencing or polymerase chain reaction (PCR) assay.
Tumor tissue must be available for retrospective biomarker analysis. Sample may be archival or new biopsy.

Exclusion Criteria

GIST that is both KIT and PDGFRA wild-type or known to harbor an activating PDGFRA exon 18 mutation.
Known untreated or active central nervous system metastases.
Participants with a known allergy or hypersensitivity to any component of IDRX-42 (GSK6042981) or sunitinib. Participants with a history of Stevens-Johnson syndrome on a prior Tyrosine kinase inhibitor (TKI) are excluded.
Has a malignancy (except disease under study) that has progressed or required active treatment within the past 24 months except for basal cell or squamous cell carcinomas of the skin or in-situ carcinomas (e.g., breast, cervix, bladder) that have been resected with no evidence of metastatic disease.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Miami?

Yes, this clinical trial (NCT07218926) has an active research site in Miami, FL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Gastrointestinal Neoplasms Treatment Options in Miami, FL

If you're searching for gastrointestinal neoplasms treatment options in Miami, FL, this clinical trial (NCT07218926) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Miami research site is actively enrolling participants for this clinical trial. You'll receive care from experienced gastrointestinal neoplasms specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all gastrointestinal neoplasms clinical trials near you to find additional studies recruiting in your area.

More Multiple Sclerosis Trials in Miami, FL

See all multiple sclerosis clinical trials recruiting in Miami — not just this study.

Browse Multiple Sclerosis Trials in Miami →

Browse More Trials by Condition

Multiple Sclerosis TrialsAnkylosing Spondylitis TrialsGeographic Atrophy TrialsOsteogenesis Imperfecta TrialsAll Conditions →

Ready to Join in Miami?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Miami, FL